RICHMOND, Calif., June 28, 2018 /PRNewswire/
-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO) today announced
the appointment of Dr. Karen Smith,
an accomplished drug development executive, to the Company's Board
of Directors.
"Karen's extensive experience in drug development, registration
and commercialization will benefit Sangamo tremendously, and I'm
pleased to welcome her to our board," said Dr. Sandy Macrae, Chief Executive Officer of
Sangamo. "Beyond her specific industry expertise, she is a strong
and accomplished leader who will help Sangamo become a fully
integrated biotechnology company delivering important new genomic
therapies to patients."
Dr. Smith has over 20 years of biopharmaceutical industry
experience in the United States,
Europe, Canada and Asia. She has overseen more than 50 clinical
trials and more than 20 regulatory approvals leading to global
product launches of small molecules, biologics and devices. Most
recently, she served as Executive Vice President, Global Head
R&D, and Chief Medical Officer of Jazz Pharmaceuticals, Inc.
Prior to joining Jazz in 2015, Dr. Smith served as Senior Vice
President, Global Medical Affairs and Global Dermatology Head for
Allergan plc. From 2008 to 2011, she held leadership positions in
External Medical Relations and Global Development at AstraZeneca,
and from 2002 to 2008 she held various senior management and
clinical roles with Bristol-Myers Squibb, including Head of U.S.
Clinical Operations. Dr. Smith currently is a member of the Board
of Directors of Acceleron Pharma and a Board Advisor for the
Australian Philanthropic 'Eliminate Cancer' Initiative. She
received a B.App.Sc. in Biotechnology and a B.Sc. in Haematology
from Curtin University of Technology,
an M.D. from the University of Warwick,
her Ph.D. in Oncology Molecular Genetics from the University of
Western Australia, an M.B.A. from
the University of New England in
Australia, and a Master of Laws
(L.L.M.) in Health Law from the University of Salford.
About Sangamo Therapeutics
Sangamo Therapeutics, Inc.
is focused on translating ground-breaking science into genomic
therapies that transform patients' lives using the Company's
platform technologies in genome editing, gene therapy, gene
regulation and cell therapy. The Company has open Phase 1/2
clinical trials in hemophilia A and hemophilia B, lysosomal storage
disorders MPS I and MPS II, as well as beta thalassemia. Sangamo
has an exclusive, global collaboration and license agreement with
Kite, a Gilead company, for engineered cell therapies for oncology,
with Pfizer Inc. for gene therapy programs for Hemophilia A, with
Bioverativ for hemoglobinopathies, including beta thalassemia and
sickle cell disease, and with Shire International GmbH to develop
therapeutics for Huntington's disease. For more information about
Sangamo, visit the Company's website at www.sangamo.com.
Forward-Looking Statements
This press release may
contain forward-looking statements based on Sangamo's current
expectations. These forward-looking statements include, without
limitation, the Company's intent to become a fully integrated
biotechnology company delivering important new genomic therapies to
patients. Actual results may differ materially from these
forward-looking statements due to a number of factors, including
risks related to the ability of the Company to successfully develop
and commercialize any of its product candidates. Additional risks
and uncertainties relating to Sangamo and its business can be found
under the heading "Risk Factors" in Sangamo's most recent Quarterly
Report on Form 10-Q for the quarter ended March 31, 2018. You should not place undue
reliance on these forward-looking statements, which apply only as
of the date of this press release. Sangamo assumes no obligation to
update the forward-looking information contained in this press
release.
View original content with
multimedia:http://www.prnewswire.com/news-releases/sangamo-therapeutics-appoints-karen-smith-to-its-board-of-directors-300674322.html
SOURCE Sangamo Therapeutics, Inc.